CD86 and neoplasm: Flow cytometry analysis confirmed the upregulation of antigen-presenting markers CD86 and MHC-I molecules in tumor-infiltrating DCs of the LR-DPVB-treated group compared to the DPVB-treated group (Supplementary Fig. 9n), indicating enhanced maturation and antigen-presenting function.